News

InCarda Therapeutics Recruiting for Phase 2 Clinical Trial in PAF

InCarda Therapeutics is currently conducting a Phase 2 clinical trial (INSTANT) in patients with symptomatic paroxysmal atrial fibrillation (PAF). For more information, please refer to the clinicaltrials.gov registration link below. https://www.clinicaltrials.gov/ct2/show/NCT03539302?term=INSTANT&cond=Atrial+Fibrillation&rank=1...

InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm™ Program, Plans for Pivotal Phase 3 Study and Expansion of Senior Management Team

Positive Data from Completed InRhythm Phase 2 Study Demonstrate Safe and Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Plans to Initiate RESTORE1: Single Pivotal Phase 3 Trial in Atrial Fibrillation in Q3 2021; Data Expected 2H 2022 Appointment of Angela Wang as CFO Strengthens...

Grace Colón Participates on Panel Hosted by Women in Bio (WIB)

YWIB-San Francisco Bay Area: Spring Into STEM–Extraordinary Leaders Transforming the Future of STEM The San Francisco Bay Area Chapter of Young Women In Bio is thrilled to bring together an extraordinary group of leaders at the forefront of science. Join us for an inspiring discussion with...

InCarda Therapeutics featured in Men’s Health

InCarda Therapeutics CEO Grace Colón was interviewed for this brief and informative piece on Atrial Fibrillation, The Hidden Heart Problem That's Claiming Men's Lives Now by Julie Stewart in the February 2021 edition of Men’s Health. Key points: “There’s a U-shaped curve with AFib—people who don’t exercise...